Key result
PAF-AH/Lp-PLA2 associates with lipoproteins in atherosclerotic lesions and offers proposed anti-inflammatory properties.
Why the study?
The role and properties of the secreted form of PAF-AH/Lp-PLA2 in inflammation and atherosclerosis remain controversial and require clarification.
Discusses the controversy surrounding the role of PAF-AH/Lp-PLA2 in inflammation and atherosclerosis.
May prompt reevaluation of Lp-PLA2 inhibition; leaves open its net role in human atherosclerosis.
The secreted or plasma form of platelet-activating factor acetylhydrolase (PAF-AH), also known as lipoprotein-associated phospholipase A2 (Lp-PLA2) or phospholipase A2 group 7 (PLA2G7), is a member of the PLA2 superfamily of enzymes that circulates in blood in association with lipoproteins, and is found in atherosclerotic lesions [reviewed in (2, 3)]. This enzyme was discovered in the early 1980s based on its ability to hydrolyze the pro-inflammatory glycerophospholipid PAF, and was thus proposed to have anti-inflammatory properties.
No takes yet. Share an insight, caveat, or question.
Stafforini et al. (2014) reported a review. PAF-AH/Lp-PLA2 was evaluated. PAF-AH/Lp-PLA2 is an enzyme associated with lipoproteins and found in atherosclerotic lesions, originally proposed to have anti-inflammatory properties.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: